Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 29c; offers guidance

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $3.95, $0.29 worse than the analyst estimate of $4.24. Revenue for the quarter came in at $892.8 million versus the consensus estimate of $896.9 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2023 EPS of $16.90-$17.85, versus the consensus of $17.44. Jazz Pharmaceuticals sees FY2023 revenue of $3.675-3.875 billion, versus the consensus of $3.78 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits